DailyDoctor Archive Specialties Get app
All obstetrics & gynaecology briefings

The edition · Obstetrics & Gynaecology

An SGLT2 inhibitor before the pregnancy test: reassuring, but imprecise

Pooled cohorts find no clear rise in malformations after early SGLT2 or GLP-1 exposure, a skin condition linked to three times the sphincter injuries, and why a pregnancy history belongs in every cardiovascular risk score.

The edition in brief

Two meta-analyses address the women who conceive on newer diabetes and weight drugs. Three cohorts with 669 SGLT2 inhibitor-exposed pregnancies found no clear rise in major congenital malformations against insulin (RR 0.94, 0.68-1.29), but certainty was low and one Korean cohort flagged a cardiac signal for exposure in weeks 4-10. Ten studies of more than two million pregnancies found no detectable rise in adverse outcomes after periconceptional GLP-1 receptor agonist exposure; neither analysis establishes safety. A Danish cohort of 277 births to women with vulvar lichen sclerosus linked the condition to more second-degree tears (RR 1.37) and anal sphincter injuries (RR 3.37), with introital narrowing and active symptoms marking the highest risk. The pearl covers postpartum blood pressure follow-up after hypertensive pregnancy. The practice changer: in a Dutch cohort of 28,234 first-time mothers, adding pregnancy factors - mainly hypertensive disorders of pregnancy - lifted a 10-year hypertension model's C-index from 0.66 to 0.77.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free